Largest Phase 3 Trial of Psilocybin for Depression Has Begun | Psychedelic spotlight

As our social fabric is unraveling and rates of depression continue to rise, affecting an estimated 310 million people worldwide, psilocybin research has given us a glimmer of hope that things may be changing for the better. The largest Phase 3 clinical trial investigating the safety, efficacy, and tolerability of psilocybin as a treatment for treatment-resistant depression (TRD) has finally begun. In late 2022, Compass Pathways announced that their Phase 3 program, consisting of two separate pivotal studies involving a total of 946 participants and one long-term follow-up study, would…

Read More